Amplimmune Articles
Drug development deals for Kyowa Hakko/Adimab, Daiichi Sankyo/Amplimmune and Chugai/Debiopharm
8 January 2013
GlaxoSmithKline signs deal with Amplimmune worth more than $500 million for AMP-224 in cancer and other diseases
5 August 2010
Showing 1-2 of 2 articles
- 1
- Elan makes "transformational" acquisitions and a divestment
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- New study shows UCB's Neupro reduces NSBP in RLS patient
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
